EBS at a glance
Emergent BioSolutions Inc. (EBS, SEC CIK 1367644) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as October 7, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Emergent BioSolutions Inc. (EBS) reported revenue of $742.9 million (down 28.8% from FY2024) and net income of $52.6 million. Diluted EPS was $0.93.
- As of September 30, 2026, 28 institutional investment managers tracked by SignalX reported holding Emergent BioSolutions Inc. (EBS) shares worth $147.9 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by DeGolyer Donald W on October 7, 2026 of 17,800 shares at $7.09 per share.
- In the last 90 days, EBS insiders reported 0 open-market purchases ($0) and 2 open-market sales ($146K) on Form 4, a net sale of $146K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $742.9M
- −28.8% vs prior year
- Insiders · 90 days
- 0 buys · 2 sells
- Net −$146K
- 13F holders
- 28 funds
- $147.9M · +1 vs prior quarter
- Latest 8-K
- Nov 4, 2026
- Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Third-party manufacturing: FDA noncompliance could halt sole-source production and interrupt customer supply
- NARCAN competition: Teva, Padagis and Amneal generics could erode sales through lower-priced or free alternatives
- Restructuring plan: August 5, 2026 workforce reductions and wet-laboratory closures may disrupt operations
- Political and social pressures: USG preference for U.S.-made products may reduce Winnipeg facility purchases
- Restructuring compliance: Workforce reductions may trigger wrongful-termination or discrimination claims under local labor laws
Management Discussion & Analysis
- Revenue $110.0M, down 52% YoY from $231.1M
- Gross margin 14% vs 54% YoY, operating loss $37.3M vs income $76.5M
- Best segment Anthrax MCM, revenue $25.1M, up $23.7M; worst Smallpox MCM, $26.7M, down 68%
- Cash and equivalents $175.7M vs $205.4M at December 31; operating cash flow $122.4M
- Debt repurchases $75.0M principal, $68.1M cash; management expects continued quarterly variability and cites NARCAN pricing and volume pressure
AI summary of the EBS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- Up to $22.3 million BioThrax order modification from the U.S. Department of War
- Approximately $7.4 million first delivery begins in 2026, remaining deliveries expected in 2027
Item EX-99.1: Item EX-99.1
- Up to $22.3 million BioThrax delivery-order modification from the U.S. Department of War
- Approximately $7.4 million initial delivery scheduled for 2026, with remaining deliveries expected in 2027
Item 2.02: Results of Operations and Financial Condition
- Emergent BioSolutions announced financial and operating results for the quarter ended September 30, 2026
- Detailed results and management commentary appear in furnished Exhibit 99.1, the company’s earnings press release
Item 7.01: Regulation FD Disclosure
- Earnings call scheduled November 2, 2026, covering results for quarter ended September 30, 2026
- Earnings Call Slides furnished as Exhibit 99.2, providing investor presentation materials for the quarterly results discussion
Item EX-99.2: Item EX-99.2
- Q3 2026 revenue $110M, within prior guidance, but YTD revenue fell to $500M from $594M
- FY 2026 guidance reduced to revenue $600M-$645M and Adjusted EBITDA $110M-$140M
Item EX-99.1: Item EX-99.1
- Q3 revenue $110.0M, down 52% year over year, with Smallpox MCM down 68% and Other Products down 87%
- Net loss $32.7M, adjusted net loss $18.7M, and adjusted EBITDA loss $4.6M, signaling sharply weaker profitability
Item 5.02: Departure/Appointment of Directors or Principal Officers
- CFO Richard Lindahl departs December 31, 2026, then advises through March 31, 2027, supporting 2026 Form 10-K preparation
- Treasurer Frank Vargo becomes Interim CFO and principal financial and accounting officer January 1, 2027
Item EX-99.1: Item EX-99.1
- CFO Richard S. Lindahl retires December 31, 2026 after nearly nine years at Emergent
- Treasurer Frank Vargo becomes interim CFO January 1, 2027, signaling internal succession and near-term continuity
AI summaries of EBS 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for EBS
Don't miss the next EBS filing
- Alerts as it files. A push when EBS files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut EBS, by share count.
- Ask anything. An AI agent that reads every EBS filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| DeGolyer Donald W | Sell | Oct 7, 2026 | 17,800 | $7.09 |
| Williams Paul Anthony | Sell | Oct 1, 2026 | 3,000 | $6.53 |
| Williams Paul Anthony | Sell | Jul 1, 2026 | 3,000 | $8.40 |
| Glessner Coleen | F | Jun 8, 2026 | 2,018 | $8.00 |
| Hartzel William | F | Jun 8, 2026 | 1,741 | $8.00 |
| Williams Paul Anthony | F | Jun 8, 2026 | 694 | $8.00 |
| LINDAHL RICHARD S | F | Jun 8, 2026 | 3,964 | $8.00 |
| Dayal Sujata Tyagi | Sell | May 1, 2026 | 12,781 | $8.36 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $1.0B | $1.0B | $742.9M |
| Operating Income | - | -$108.7M | $100.1M |
| Net Income | - | -$190.6M | $52.6M |
| Op. Margin | - | -10.4% | 13.5% |
| Net Margin | - | -18.3% | 7.1% |
| Balance Sheet | |||
| Total Assets | $1.8B | $1.4B | $1.3B |
| Equity | $649.3M | $482.8M | $522.6M |
| ROE | - | -39.5% | 10.1% |
| Per Share | |||
| EPS | - | $-3.60 | $0.93 |
| Cash Flow | |||
| Operating CF | - | $58.7M | $170.6M |
| CapEx | $51.6M | $22.9M | $13.8M |
Source: XBRL data in Emergent BioSolutions Inc. (EBS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate EBS share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 28 | $147.9M |
| Q2 2026 | 27 | $186.1M |
| Q1 2026 | 28 | $172.5M |
| Q4 2025 | 27 | $236.3M |
| Q3 2025 | 28 | $158.7M |
| Q2 2025 | 26 | $113.2M |
| Q1 2025 | 21 | $71.0M |
| Q4 2024 | 18 | $115.5M |
- Millennium Management+809.4K (+75%)
- BlackRock+453.0K (+10%)
- Truist Financial+186.4K (+427%)
- Vanguard Portfolio Management LLC+145.0K (+14%)
- Morgan Stanley+76.0K (+16%)
- Dimensional Fund Advisors−509.5K (-17%)
- Two Sigma Investments−328.7K (-67%)
- State Street Corp−216.0K (-7%)
- Goldman Sachs Group−123.9K (-12%)
- AQR Capital Management−123.3K (-12%)
- Principal Financial Group+152.6K
- M&T Bank+20.8K
- Citadel Advisors LLC+12.9K
- FMR LLC (Fidelity)−214.2K
- Franklin Resources−166.8K
Source: 13F-HR filings on SEC EDGAR (aggregated from 203 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
EBS filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 10-Q | Nov 3, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 2, 2026 | - | Analysis | - |
| 8-K | Oct 16, 2026 | - | Analysis | - |
| 4 | Oct 7, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 8-K | Sep 14, 2026 | - | Analysis | - |
| 8-K | Sep 1, 2026 | - | Analysis | - |
| SC 13G | Aug 14, 2026 | - | - | |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 4 | Jul 2, 2026 | - | - | - |
| 8-K | Jun 29, 2026 | - | Analysis | - |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | May 4, 2026 | - | - | - |
| 4 | May 4, 2026 | - | - | - |
| 4 | May 4, 2026 | - | - | - |
| 4 | May 4, 2026 | - | - | - |
| 4 | May 4, 2026 | - | - | - |
| 4 | May 4, 2026 | - | - | - |
| 4 | May 4, 2026 | - | - | - |
| 4 | May 4, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
EBS SEC filings: frequently asked questions
Are EBS insiders buying or selling?
In the last 90 days, Emergent BioSolutions Inc. (EBS) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $145,792 by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold EBS stock?
As of September 30, 2026, the largest Emergent BioSolutions Inc. (EBS) holders among the 13F filers tracked by SignalX were BlackRock ($34.1 million), State Street Corp ($17.9 million), Dimensional Fund Advisors ($16.9 million), Vanguard Capital Management LLC ($14.3 million), Millennium Management ($12.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was EBS's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Emergent BioSolutions Inc. (EBS) reported revenue of $742.9 million (down 28.8% from FY2024) and net income of $52.6 million. Diluted EPS was $0.93. The figures come from the XBRL data in the 10-K.
What did EBS report in its latest 8-K?
Emergent BioSolutions Inc. (EBS) filed an 8-K on November 4, 2026 reporting Item 8.01 (Other Events). Up to $22.3 million BioThrax order modification from the U.S. Department of War.
What are the latest EBS SEC filings?
Emergent BioSolutions Inc. (EBS) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on October 7, 2026.
What is EBS's SEC CIK number?
Emergent BioSolutions Inc. (EBS)'s SEC Central Index Key (CIK) is 1367644. EDGAR lists every EBS filing under that number.
Ask anything about EBS
The research agent reads EBS's filings, financials, insider trades and 13F holders, then answers with sources.